Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-17T16:20:55.420Z Has data issue: false hasContentIssue false
  • English
  • Français

Effectiveness of a vancomycin dosing protocol guided by area under the concentration-time curve to minimal inhibitory concentration (AUC/MIC) with multidisciplinary team support to improve hospital-wide adherence to a vancomycin dosing protocol: A pilot study

Published online by Cambridge University Press:  12 July 2021

Panipak Katawethiwong ,
Anucha Apisarnthanarak ,
Kittiya Jantarathaneewat ,
David J. Weber ,
David K. Warren  and
Nuntra Suwantarat Open the ORCID record for Nuntra Suwantarat [Opens in a new window]
Panipak Katawethiwong
Affiliation:
Division of Infectious Diseases, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
Anucha Apisarnthanarak
Affiliation:
Division of Infectious Diseases, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
Kittiya Jantarathaneewat
Affiliation:
Department of Pharmaceutical Care, Faculty of Pharmacy, Thammasat University, Pathum Thani, Thailand
David J. Weber
Affiliation:
Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, United States
David K. Warren
Affiliation:
Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri, United States
Nuntra Suwantarat*
Affiliation:
Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand
*
Author for correspondence: Nuntra Suwantarat, E-mail: nsuwantarat@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Limited data are available on the implementation of an area under the concentration-time curve (AUC)–based dosing protocol with multidisciplinary team (MT) support to improve adherence with vancomycin dosing protocol.

Objective:

To evaluate the effectiveness of an AUC-based dosing protocol with MT support intervention with adherence to a hospital-wide vancomycin dosing protocol at Thammasat University Hospital.

Method:

We conducted a quasi-experimental study in patients who were prescribed intravenous vancomycin. The study was divided into 2 periods; (1) the preintervention period when the vancomycin dosing protocol was already applied in routine practice and (2) the post-intervention period when the implementation of an AUC-based dosing protocol with MT support was added to the existing vancomycin dosing protocol. The primary outcome was the rate of adherence, and the secondary outcomes included acute kidney injury events, vancomycin-related adverse events, and 30-day mortality rate.

Results:

In total, 240 patients were enrolled. The most common infections were skin and soft-tissue infections (24.6%) and bacteremia (24.6%). The most common pathogens were coagulase-negative staphylococci (19.6%) and Enterococcus spp (15.4%). Adherence with the vancomycin dosing protocol was significantly higher in the postintervention period (90.8% vs 55%; P ≤ .001). By multivariate analysis, an AUC-based dosing protocol with MT support was the sole predictor for adherence with the vancomycin dosing protocol (adjusted odds ratio, 10.31; 95% confidence interval, 4.54–23.45; P ≤ .001). The 30-day mortality rate was significantly lower during the postintervention period (8.3% vs 20%; P = .015).

Conclusions:

AUC-based dosing protocol with MT support significantly improved adherence with vancomycin dosing protocol and was associated with a lower 30-day mortality rate.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 8 , August 2022 , pp. 1043 - 1048
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rybak, MJ, Le, J, Lodise, TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2020;77:835–864.CrossRefGoogle Scholar
Meng, L, Wong, T, Huang, S, et al. Conversion from vancomycin trough concentration–guided dosing to area under the curve–guided dosing using two sample measurements in adults: Implementation at an Academic Medical Center. Pharmacotherapy 2019;39:433–442.CrossRefGoogle ScholarPubMed
Finch, NA, Zasowski, EJ, Murray, KP, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother 2017;61(12):e01293–17.CrossRefGoogle Scholar
Neely, MN, Kato, L, Youn, G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother 2018;62(2):e02042–17.CrossRefGoogle ScholarPubMed
Suchartlikitwong, P, Anugulruengkitt, S, Wacharachaisurapol, N, et al. Optimizing vancomycin use through 2-point AUC-based therapeutic drug monitoring in pediatric patients. J Clin Pharmacol 2019;59:1597–1605.CrossRefGoogle ScholarPubMed
Chen, Y, Wu, D, Dong, M, et al. Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol 2018;74:921–930.CrossRefGoogle ScholarPubMed
Mizokami, F, Shibasaki, M, Yoshizue, Y, Noro, T, Mizuno, T, Furuta, K. Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging 2013;8:1015–1021.CrossRefGoogle ScholarPubMed
Fukumori, S, Tsuji, Y, Mizoguchi, A, et al. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia. J Clin Pharm Ther 2016;41:399–402.CrossRefGoogle ScholarPubMed
Chan, JOS, Baysari, MT, Carland, JE, Sandaradura, I, Moran, M, Day, RO. Barriers and facilitators of appropriate vancomycin use: prescribing context is key. Eur J Clin Pharmacol 2018;74:1523–1529/CrossRefGoogle Scholar
Phillips, CJ, Wisdom, AJ, McKinnon, RA, Woodman, RJ, Gordon, DL. Interventions targeting the prescribing and monitoring of vancomycin for hospitalized patients: a systematic review protocol. Infect Dis Ther 2017;6:557–563.CrossRefGoogle ScholarPubMed
Chattaweelarp, T, Changpradub, D, Punyawudho, B, Thunyaharn, S, Santimaleeworagun, W. Is early monitoring better? Impact of early vancomycin exposure on treatment outcomes and nephrotoxicity in patients with methicillin-resistant Staphylococcus aureus infections. Antibiotics (Basel) 2020;9:672.CrossRefGoogle ScholarPubMed
Pongchaidecha, M, Changpradub, D, Bannalung, K, et al. Vancomycin area under the curve and pharmacokinetic parameters during the first 24 hours of treatment in critically ill patients using Bayesian forecasting. Infect Chemother 2020;52:573–582.CrossRefGoogle ScholarPubMed
Rybak, MJ, Lomaestro, BM, Rotschafer, JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275–1279.CrossRefGoogle Scholar
Chapter 1: Definition and classification of CKD. Kidney Int Suppl 2013;3:19–62.CrossRefGoogle Scholar
Khwaja, A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120:c179–c184.CrossRefGoogle ScholarPubMed
Miloslavsky, M, Galler, MF, Moawad, I, Actis, J, Cummings, BM, El Saleeby, CM. The impact of pediatric-specific vancomycin dosing guidelines: a quality improvement initiative. Pediatrics 2017;139(6):e20162423.CrossRefGoogle ScholarPubMed
Dib, JG, Al-Tawfiq, JA, Al Abdulmohsin, S, Mohammed, K, Jenden, PD. Improvement in vancomycin utilization in adults in a Saudi Arabian medical center using the Hospital Infection Control Practices Advisory Committee guidelines and simple educational activity. J Infect Public Health 2009;2:141–146.CrossRefGoogle Scholar
Phillips, CJ, Gordon, DL. Pharmacist-led implementation of a vancomycin guideline across medical and surgical units: impact on clinical behavior and therapeutic drug monitoring outcomes. Integr Pharm Res Pract 2015;4:145–152.CrossRefGoogle ScholarPubMed
Phillips, CJ, McKinnon, RA, Woodman, RJ, Gordon, DL. Sustained improvement in vancomycin dosing and monitoring post-implementation of guidelines: results of a three-year follow-up after a multifaceted intervention in an Australian teaching hospital. J Infect Chemother 2018;24:103–109.CrossRefGoogle Scholar
Traugott, KA, Maxwell, PR, Green, K, Frei, C, Lewis, JS 2nd. Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm 2011;68:347–352.CrossRefGoogle Scholar
Smith, AP, Millares-Sipin, CA, James, M, Cohen, H. Impact of a Pharmacist-Initiated Vancomycin Monitoring Program. Consult Pharm 2016;31:505–510.CrossRefGoogle ScholarPubMed
Faine, B, Mohr, N, Harland, KK, Rolfes, K, Porter, B, Fuller, BM. Importance of decision support implementation in emergency department vancomycin dosing. West J Emerg Med 2015;16:557–564.CrossRefGoogle ScholarPubMed
Choi, R, Woo, HI, Park, HD, Lee, SY. A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea. Infect Drug Resist 2019;12:2163–2173.CrossRefGoogle ScholarPubMed
Tsutsuura, M, Moriyama, H, Kojima, N, et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. BMC Infect Dis 2021;21(1):153.CrossRefGoogle ScholarPubMed
Ghosh, N, Chavada, R, Maley, M, van Hal, SJ. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2014;20:O1098–O1105.CrossRefGoogle ScholarPubMed
Neely, MN, Youn, G, Jones, B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014;58:309–316.CrossRefGoogle ScholarPubMed
Hale, CM, Seabury, RW, Steele, JM, Darko, W, Miller, CD. Are vancomycin trough concentrations of 15 to 20 mg/L associated with increased attainment of an AUC/MIC ≥ 400 in patients with presumed MRSA infection? J Pharm Pract 2017;30:329–335.CrossRefGoogle ScholarPubMed
Men, P, Li, HB, Zhai, SD, Zhao, RS. Association between the AUC0-24/MIC ratio of vancomycin and its clinical effectiveness: a systematic review and meta-analysis. PLoS One 2016;11:e0146224.CrossRefGoogle ScholarPubMed
Prybylski, JP. Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies. Pharmacotherapy 2015;35:889–898.CrossRefGoogle ScholarPubMed
Lodise, TP, Rosenkranz, SL, Finnemeyer, M, et al. The emperor’s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis 2020;70:1536–1545.CrossRefGoogle Scholar
Supplementary material: File

Katawethiwong et al. supplementary material

Katawethiwong et al. supplementary material

Download Katawethiwong et al. supplementary material(File)
File 16.8 KB